Drugbank Logo

Search Results

Search for "Hyperparathyroidism" returned 4 results

Showing 1-4 out of 4
DrugBank ID Name Formula Weight
DB01012
DrugCard button for DB01012
Cinacalcet C22H22F3N 357.4120
Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure. Tablet Oral 02257157 DB01012 Terminal half ...
DB00910
DrugCard button for DB00910
Paricalcitol C27H44O3 416.6365
... to 6 hours BPKAHTKRCLCHEA-UBFJEZKGBX For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4 (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6 ...
DB00258
DrugCard button for DB00258
Calcium Acetate C4H6CaO4 158.1660
... of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to ...
DB00658
DrugCard button for DB00658
Sevelamer C6H12ClNO 149.6190
Hyperphosphatemia plays a role in the development of secondary hyperparathyroidism in renal insufficiency. An increase in parathyroid hormone (PTH) levels is characteristic of patients with ...
Showing 1-4 out of 4

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.